Home > Integrin & Integrin & > Cilengitide

Cilengitide

西仑吉肽,EMD-121974,NSC-707544

Cilengitide是一种有效的integrin(整合素)抑制剂,作用于αvβ3受体和αvβ5受体,IC50分别为4.1 nM和79 nM,比作用于gpIIbIIIa选择性高10倍左右。

目录号
EY1634
EY1634
纯度
99.24%
99.24%
规格
5 mg
10 mg
原价
1190
1590
售价
1190
1590
库存
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    Cilengitide (EMD 121974, NSC 707544) is a selective inhibitor of αvβ3 integrin and αvβ5 integrin with IC50 of 1 nM and 140 nM, respectively.

  • 体外研究

  • 体内研究

    30% propylene glycol, 5% Tween 80, 65% D5W(5%葡萄糖水溶液)

  • 激酶实验

  • 细胞实验

    1-50 μg/mL

  • 动物实验

    100μg每天腹腔注射

  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Reardon DA, et al. Genes Cancer, 2011, 2(12):1159-1165.
    [2] Alghisi et al (2009) The integrin antagonist cilengitide activates αvβ3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One 4 e4449.
    [3] Monnier et al (2008) CYR61 and αvβ5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 68 7323.

    分子式
    C27H40N8O7
    分子量
    588.66
    CAS号
    188968-51-6
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    Water
    10 mg/mL
    Ethanol

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01118676 Locally Advanced Non Small Cell Lung Cancer (NSCLC)* Drug: cilengitide, radiochemotherapy Institut Claudius Regaud|Merck KGaA Phase 1 2010-03-01 2015-09-03
    NCT00063973 Childhood Central Nervous System Germ Cell Tumor|Childhood Choroid Plexus Tumor|Childhood Craniopharyngioma|Childhood Ependymoblastoma|Childhood Grade I Meningioma|Childhood Grade II Meningioma|Childhood Grade III Meningioma|Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Childhood Infratentorial Ependymoma|Childhood Low-grade Cerebellar Astrocytoma|Childhood Low-grade Cerebral Astrocytoma|Childhood Medulloepithelioma|Childhood Mixed Glioma|Childhood Oligodendroglioma|Childhood Supratentorial Ependymoma|Recurrent Childhood Brain Stem Glioma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Ependymoma|Recurrent Childhood Medulloblastoma|Recurrent Childhood Pineoblastoma|Recurrent Childhood Subependymal Giant Cell Astrocytoma|Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor|Recurrent Childhood Visual Pathway and Hypothalamic Glioma Drug: cilengitide|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 1 2003-07-01 2013-09-27
    NCT00679354 Childhood High-grade Cerebellar Astrocytoma|Childhood High-grade Cerebral Astrocytoma|Recurrent Childhood Anaplastic Astrocytoma|Recurrent Childhood Anaplastic Oligoastrocytoma|Recurrent Childhood Anaplastic Oligodendroglioma|Recurrent Childhood Brain Tumor|Recurrent Childhood Cerebellar Astrocytoma|Recurrent Childhood Cerebral Astrocytoma|Recurrent Childhood Glioblastoma|Recurrent Childhood Visual Pathway and Hypothalamic Glioma Drug: cilengitide|Other: laboratory biomarker analysis|Other: pharmacological study National Cancer Institute (NCI) Phase 2 2008-06-01 2014-05-05
    NCT00121238 Recurrent Prostate Cancer|Stage I Prostate Cancer|Stage IIA Prostate Cancer|Stage IIB Prostate Cancer|Stage III Prostate Cancer Drug: cilengitide National Cancer Institute (NCI) Phase 2 2005-01-01 2016-03-28
    NCT01165333 Diffuse Intrinsic Pontine Glioma Drug: Cilengitide dose escalation|Drug: Cilengitide|Radiation: Concomitant radiotherapy|Biological: Pharmacokinetic|Biological: Pharmacogenetic|Biological: Exploratory investigation Centre Oscar Lambret Phase 1 2010-08-01 2016-02-15
    NCT00103337 Recurrent Prostate Cancer|Stage IV Prostate Cancer Drug: cilengitide|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 2 2005-01-01 2013-02-27
    NCT00089388 Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b) Drug: cilengitide National Cancer Institute (NCI) Phase 2 2004-07-01 2013-01-23
    NCT01782976 Glioblastoma Drug: Cilengitide|Drug: Bevacizumab|Behavioral: Questionnaire M.D. Anderson Cancer Center|Brain Tumor Trials Collaborative|EMD Serono Phase 2 2013-06-01 2013-09-03
    NCT00979862 Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Neoplasm Drug: Cediranib Maleate|Drug: Cilengitide|Other: Laboratory Biomarker Analysis National Cancer Institute (NCI) Phase 1 2010-03-01 2015-04-14
    NCT01124240 Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4 Drug: Cilengitide Northern Sydney and Central Coast Area Health Service|Merck KGaA Phase 2 2009-11-01 2011-07-25
    NCT01276496 Adult Solid Neoplasm|Estrogen Receptor Negative|HER2/Neu Negative|Male Breast Carcinoma|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma Drug: Cilengitide|Other: Laboratory Biomarker Analysis|Drug: Paclitaxel|Other: Pharmacological Study National Cancer Institute (NCI) Phase 1 2010-12-01 2016-03-14
    NCT00689221 Glioblastoma Drug: Cilengitide|Drug: Temozolomide|Radiation: Radiotherapy EMD Serono|European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA Phase 3 2008-09-01 2014-10-28
    NCT01558687 Supratentorial Newly Diagnosed Inoperable Gliobastoma Drug: Drug (including placebo)|Other: Standard therapy Merck KGaA Phase 1 2012-08-01 2014-02-03
    NCT00813943 Glioblastoma Drug: Cilengitide (2-times weekly)|Drug: cilengitide (5-times weekly)|Drug: Temozolomide|Radiation: Radiotherapy EMD Serono|Merck KGaA Phase 2 2009-03-01 2017-01-12
    NCT00082875 Stage III Melanoma|Stage IV Melanoma Drug: cilengitide|Other: pharmacological study|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 2 2004-03-01 2013-06-04
    NCT00077155 AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Primary CNS Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Hodgkin Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Stage III Adult Burkitt Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Adult Diffuse Mixed Cell Lymphoma|Stage III Adult Diffuse Small Cleaved Cell Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage III Adult Immunoblastic Large Cell Lymphoma|Stage III Adult Lymphoblastic Lymphoma|Stage III Cutaneous T-cell Non-Hodgkin Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage III Marginal Zone Lymphoma|Stage III Mycosis Fungoides/Sezary Syndrome|Stage III Small Lymphocytic Lymphoma|Stage IV Adult Burkitt Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Adult Diffuse Mixed Cell Lymphoma|Stage IV Adult Diffuse Small Cleaved Cell Lymphoma|Stage IV Adult Hodgkin Lymphoma|Stage IV Adult Immunoblastic Large Cell Lymphoma|Stage IV Adult Lymphoblastic Lymphoma|Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma|Stage IV Marginal Zone Lymphoma|Stage IV Mycosis Fungoides/Sezary Syndrome|Stage IV Small Lymphocytic Lymphoma|Unspecified Adult Solid Tumor, Protocol Specific Drug: cilengitide National Cancer Institute (NCI) Phase 1 2003-12-01 2013-01-23
    NCT01122888 Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Solid Neoplasm|Recurrent Adult Brain Neoplasm Drug: Cilengitide|Other: Clinical Observation|Other: Laboratory Biomarker Analysis National Cancer Institute (NCI) Phase 1 2009-12-01 2015-04-27
    NCT01044225 Glioblastoma Drug: Cetuximab|Drug: Cilengitide EMD 121974 Bart Neyns|Universitair Ziekenhuis Brussel Phase 2 2009-09-01 2012-03-21
    NCT00705016 Squamous Cell Cancer Drug: Cilengitide 2000 mg once weekly|Drug: Cilengitide 2000 mg twice weekly|Drug: Cetuximab|Drug: 5-fluorouracil (5-FU)|Drug: Cisplatin Merck KGaA Phase 1|Phase 2 2008-10-01 2014-03-28
    NCT00884598 Brain and Central Nervous System Tumors|Lung Cancer Drug: cilengitide|Other: pharmacological study|Radiation: radiation therapy Universit盲tsmedizin Mannheim|Heidelberg University Phase 1 2008-12-01 2010-04-27
    NCT00112866 Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Recurrent Adult Brain Tumor Drug: cilengitide|Procedure: therapeutic conventional surgery|Other: pharmacological study|Other: laboratory biomarker analysis National Cancer Institute (NCI) Phase 2 2005-01-01 2013-10-25
    NCT01504165 Renal Impairment Drug: cilengitide 2000mg|Drug: cilengitide 2000mg|Drug: cilengitide 2000mg|Drug: cilengitide 1000mg|Drug: cilengitide > 1000mg and up to 2000mg Merck KGaA Phase 1 2012-01-01 2014-02-03
    NCT00842712 Carcinoma, Non-Small-Cell Lung Drug: Cilengitide|Drug: Cilengitide|Drug: Cetuximab|Drug: Cisplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Vinorelbine|Drug: Cilengitide|Drug: Cilengitide|Drug: Cetuximab|Drug: Chemotherapy Merck KGaA Phase 2 2009-02-01 2017-01-12

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :